<DOC>
	<DOC>NCT00232089</DOC>
	<brief_summary>This study is being done to evaluate the safety, tolerability and satisfactory relief of dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will be evaluated at 6mg twice daily and placebo.</brief_summary>
	<brief_title>Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Female patients, 18 years and older Selfreported presence of persistent or recurrent adverse digestive symptoms consistent with dyspepsia; for at least 12 weeks, not necessarily consecutive, during the previous 12 months. Abnormal esophagogastroduodenoscopy (EGD) endoscopy findings such as any esophageal mucosal break, gastric erosions, gastric ulcers and/or duodenal ulcers/erosions on an EDG exam performed with 12 weeks prior to baseline. Current or history of erosive esophagitis confirmed by EGD Heartburn occurring 3 or more days a week. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dyspepsia, gastrointestinal, tegaserod</keyword>
</DOC>